Literature DB >> 2066953

Severe pancytopenia in a patient taking low dose methotrexate and probenecid.

K S Basin1, A Escalante, T D Beardmore.   

Abstract

A patient with rheumatoid arthritis developed life-threatening pancytopenia resulting from low dose oral methotrexate (MTX) toxicity potentiated by probenecid. Clinically significant drug interactions are not frequently cited as risk factors for MTX hematologic toxicity. As low dose MTX is gaining increasing popularity in rheumatologic practice, these potentially serious interactions should be considered.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2066953

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

Review 1.  Clinically relevant drug-drug interactions in oncology.

Authors:  H L McLeod
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

Review 2.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

3.  Fatal outcome of low-dose methotrexate therapy in rheumatoid arthritis.

Authors:  R Omdal; L Gøransson; H Bergrem
Journal:  Clin Rheumatol       Date:  1993-06       Impact factor: 2.980

Review 4.  Drug interactions in childhood cancer.

Authors:  Cyrine Haidar; Sima Jeha
Journal:  Lancet Oncol       Date:  2010-09-22       Impact factor: 41.316

5.  Use of methotrexate in older patients. A risk-benefit assessment.

Authors:  S E Tett; E J Triggs
Journal:  Drugs Aging       Date:  1996-12       Impact factor: 3.923

Review 6.  Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases.

Authors:  Jirí Grim; Jaroslav Chládek; Jirina Martínková
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 7.  Slow-acting antirheumatic drugs. Drug interactions of clinical significance.

Authors:  R A Munro; R D Sturrock
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

8.  Impact of omeprazole on the plasma clearance of methotrexate.

Authors:  T Reid; A Yuen; M Catolico; R W Carlson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Clinical pharmacology: special safety considerations in drug development and pharmacovigilance.

Authors:  Kwame N Atuah; Dyfrig Hughes; Munir Pirmohamed
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 10.  Methotrexate in rheumatoid arthritis. An update.

Authors:  B Bannwarth; L Labat; Y Moride; T Schaeverbeke
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.